Karnataka’s Shilpa Medicare based out of Raichur and Hubballi partners with Cadila Healthcare for the production of its Covid-19 vaccine, ZyCoV-D. The vaccine was granted the Emergency Use Authorisation (EUA) by the Indian drug regulator on August 20.

This is the second time that the Shilpa which is a listed company on the national bourses has been identified to manufacture Covid-19 vaccine, the earlier pact was with Dr Reddy’s for the production of Sputnik.

According to the communication issued by Cadila on BSE, “Te company has, entered into a definitive agreement with Shilpa Medicare, via its wholly owned subsidiary, Shilpa Biologicals for production-supply of the ZyCoV-D vaccine drug substance from its integrated biologics R&D cum manufacturing center at Dharwad, Karnataka," Cadila Healthcare.

The targeted production of the ZyCoV-D vaccine from this facility will be mutually agreed upon by both parties, it added.

"The company will transfer the ZyCoV-D technology to Shilpa Biologicals Pvt Ltd (SBPL). Under the agreement, SBPL will be responsible for manufacture of the drug substance of the vaccine, while the company is responsible for filling/packaging/distribution/marketing of the vaccine in its marketing territories," Cadila Healthcare said.